Lee, Sun Ku <br/><br/>
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.  [electronic resource] 

 -  European journal of clinical pharmacology  Jun 2017 
 - 689-698 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1432-1041 
<br/><br/><label>Standard No.: </label>10.1007/s00228-017-2226-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Agammaglobulinaemia Tyrosine Kinase<br/>Antigens, CD--metabolism<br/>Antigens, Differentiation, T-Lymphocyte--metabolism<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Interactions<br/>Half-Life<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Lectins, C-Type--metabolism<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Oligopeptides--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Young Adult